Generation Bio Co. (GBIO)
| Market Cap | 303.10M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -136.64M |
| Shares Out | 59.67M |
| EPS (ttm) | -2.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,589,628 |
| Open | 5.00 |
| Previous Close | 5.00 |
| Day's Range | 4.71 - 5.19 |
| 52-Week Range | 3.40 - 9.59 |
| Beta | 1.95 |
| Analysts | Buy |
| Price Target | 13.26 (+161.02%) |
| Earnings Date | May 4, 2023 |
About GBIO
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for GBIO stock is "Buy." The 12-month stock price forecast is $13.26, which is an increase of 161.02% from the latest price.
News
Generation Bio, Moderna announce collaboration
Shares of Generation Bio Co. GBIO, -0.51% jumped about 28% premarket trading on Thursday after the company announced a collaboration with Moderna Inc. MRNA, -2.58% to to develop novel nucleic acid the...
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
Collaboration will extend the applications of each company's platform through discovery and development of novel lipid nanoparticles using Generation Bio's proprietary stealth cell-targeted lipid nano...
Generation Bio to Participate in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...
Generation Bio to Present at the 43rd Annual Cowen Healthcare Conference
CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...
Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results
— Company expects to announce data for Factor VIII expression in non-human primates in 2023
Generation Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...
Can Generation Bio Co. (GBIO) Climb 184% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 183.8% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable...
Wall Street Analysts Think Generation Bio Co. (GBIO) Could Surge 176%: Read This Before Placing a Bet
The consensus price target hints at a 176% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...
Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results
Cash balance of $301.2M expected to fund operations into 2025 Cash balance of $301.2M expected to fund operations into 2025
Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announc...
Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer
CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announc...
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -4.76% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results
Cash balance of $312.2M expected to fund operations into 2025 Cash balance of $312.2M expected to fund operations into 2025
Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...
Generation Bio Appoints Dannielle Appelhans to Its Board of Directors
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...
Wall Street Analysts See a 174% Upside in Generation Bio Co. (GBIO): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 173.7% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable...
Generation Bio to Present at the 2022 Jefferies Healthcare Conference
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...
Generation Bio Co. (GBIO) Reports Q1 Loss, Lags Revenue Estimates
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -17.31% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results
Company continues to optimize cell-targeted lipid nanoparticle (ctLNP) delivery system for nonviral genetic medicine applications in liver, retina and vaccines
Generation Bio to Participate in 21st Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announc...
Generation Bio Co. (GBIO) Upgraded to Buy: Here's Why
Generation Bio Co. (GBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in Generation Bio Co. (GBIO)? Wall Street Analysts Think 505%
The consensus price target hints at a 504.9% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...
Generation Bio to Participate in 42nd Annual Cowen Health Care Conference
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announc...
Generation Bio Outlines 2022 Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024 Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024
Generation Bio Promotes Antoinette Paone, M.S., MBA to Chief Operating Officer
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...